What the FDA labels say about taking them together
Amlodipine and tacrolimus
Amlodipine's FDA label of February 15, 2023 names tacrolimus in its drug interactions section; tacrolimus's label does not name amlodipine itself but warns about its class (Calcium channel blockers, Calcium channel blockers (dihydropyridines)). The amlodipine label: “Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.”
Check it at the source: the amlodipine FDA label on DailyMed (effective February 15, 2023, Viatris Specialty LLC); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).
What does the amlodipine label say about tacrolimus?
Amlodipine label, drug interactionsImmunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.
Source: FDA drug label (Norvasc), Viatris Specialty LLC, effective February 15, 2023 (SPL set 7367289c-b0b0-466a-83e2-558e2985c29f), via openFDA; the full label on DailyMed
What does the tacrolimus label say about amlodipine?
Tacrolimus's label does not name amlodipine itself; it warns about its class (Calcium channel blockers, Calcium channel blockers (dihydropyridines)):
Tacrolimus label, drug interactionsClotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions (5.6 , 5.11 , 5.12 )].
Tacrolimus label, drug interactionsMild or Moderate CYP3A Inhibitors, such as: antibiotics (e.g., erythromycin), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole, azole antifungals (e.g., clotrimazole, fluconazole, isavuconazole), imatinib, nilotinib, letermovir May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions …
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amlodipine | Tacrolimus | |
|---|---|---|
| Labeled for | High blood pressure, Angina, Heart attack and coronary artery disease | Organ transplant rejection, Eczema (atopic dermatitis) |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0102 per tablet 5 mg tablet | $0.970 per gram 0.1% ointment |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once